Teva Pharmaceutical Industries Launches Authorized Generic Of Victoza In United States
Teva Pharmaceutical Industries Launches Authorized Generic Of Victoza In United States
梯瓦製藥的授權版優降糖胰島素在美國上市
- Generic Victoza is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market.
-
This launch adds to Teva's continued commitment to its complex generic medicine portfolio.
- Liraglutide injection is indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
- 普通維多利亞是首個通用的GLP-1，支持美國市場在這一類療法的需求增加。
-
此次發佈是Teva繼續致力於其複雜通用藥品組合的一部分。
- 利拉魯肽注射液適用於改善10歲及以上的成人和兒童2型糖尿病患者的血糖控制，並且降低已建立心血管疾病的成人2型糖尿病患者的心血管事件風險。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。